MELBOURN, England, June 22, 2015 /PRNewswire/ --
Aegate, the leading experts in medicines verification, have been appointed by the European Medicines Verification Organisation (EMVO) as a selected Service Provider for the supply of the Advanced National Blueprint Service.
Aegate's National Blueprint Service will ensure an end-to-end national system of medicines authentication at point of dispense, ensuring patient safety at the last point of the legal pharmaceutical supply chain.
The Falsified Medicines Directive will mandate a 3 year timeline for all pharmacies in Europe to be equipped with authentication software that meets agreed legislative requirements - with seven years' operational experience in multiple European countries, Aegate are ideally placed to lead this activity.
Aegate are pleased to be working with the EMVO and local National Medicines Verification Organisations in the fight against counterfeit medicines.
"Aegate are delighted to have been appointed as an official National Blueprint System provider. This is an important milestone in the fight against falsified medicines in Europe. Aegate are looking forward to engage with local stakeholders in the delivery of such systems," said Mark De Simone CEO.
With a documented history of some 3.3 billion medicines scanned to date with an average rate of 200,000 transactions per hour across 20,000 dispensing points, Aegate is the principal active market leader in medicines verification. Aegate's Reach, Assure and Protect services meets the needs of all stakeholders. Supported internationally by manufacturers and pharmacists alike, Aegate is a European company with offices throughout Europe. Our mission is to protect patients from falsified, recalled or expired medicines.
We operate a highly secure real‐time system to verify the authenticity of medicines. This operates seamlessly from manufacturer to pharmacy, and fully meets the requirements of European legislation for falsified medicines. The Aegate network also supports messaging services that provide additional information for the pharmacist at the point of dispense, such as regulatory or drug safety advice and patient education or adherence information.
For more information on Aegate, please visit http://www.aegate.com
Media contact information:
Head of Marketing & Communications